Print this page
-
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
Protocol: 042305Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A First-in-Human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors.
Protocol: 052006Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.
Protocol: 052008Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site -
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and In Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors.
Protocol: 052208Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase IA/IB, Open Label, Multicenter, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Protocol: 052212Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in
Subjects with Ovarian Cancer.
Protocol: 052306Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Ovary -
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations.
Protocol: 052308Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies.
Protocol: 052310Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies.
Protocol: 052401Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors.
Protocol: 052404Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies.
Protocol: 052405Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase Ia/Ib, Open-Label, Multicenter study to evaluate the Safety, Pharmacokinetics, and activity of Ro7759065 as a single agent and in combination with ATEZOLIZUMAB in Patients with locally advanced or metastatic solid tumors
Protocol: 052406Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site